Log in

NASDAQ:GTHXG1 Therapeutics News Headlines

$15.57
+0.18 (+1.17 %)
(As of 08/5/2020 04:00 PM ET)
Add
Compare
Today's Range
$15.04
Now: $15.57
$15.83
50-Day Range
$14.67
MA: $20.34
$24.37
52-Week Range
$8.80
Now: $15.57
$41.80
Volume753,214 shs
Average Volume475,297 shs
Market Capitalization$587.61 million
P/E RatioN/A
Dividend YieldN/A
Beta2.04

Headlines

G1 Therapeutics (NASDAQ GTHX) News Headlines

Source:
DateHeadline
G1 Therapeutics (GTHX) CEO Mark Velleca on Q2 2020 Results - Earnings Call TranscriptG1 Therapeutics' (GTHX) CEO Mark Velleca on Q2 2020 Results - Earnings Call Transcript
seekingalpha.com - August 6 at 1:57 AM
G1 Therapeutics EPS in-line, misses on revenueG1 Therapeutics EPS in-line, misses on revenue
seekingalpha.com - August 5 at 8:57 PM
G1 Therapeutics Provides Second Quarter 2020 Corporate and Financial UpdateG1 Therapeutics Provides Second Quarter 2020 Corporate and Financial Update
finance.yahoo.com - August 5 at 8:57 PM
G1 Therapeutics to Participate in BTIG and Wedbush Healthcare Conferences in August 2020G1 Therapeutics to Participate in BTIG and Wedbush Healthcare Conferences in August 2020
finance.yahoo.com - August 4 at 8:35 AM
G1 Therapeutics (GTHX) Buy Rating Reaffirmed at Needham & Company LLCG1 Therapeutics' (GTHX) Buy Rating Reaffirmed at Needham & Company LLC
americanbankingnews.com - August 4 at 6:14 AM
G1 Therapeutics inks trilaciclib pact with Simcere in Greater ChinaG1 Therapeutics inks trilaciclib pact with Simcere in Greater China
seekingalpha.com - August 3 at 5:31 PM
HC Wainwright Reiterates Buy Rating for G1 Therapeutics (NASDAQ:GTHX)HC Wainwright Reiterates Buy Rating for G1 Therapeutics (NASDAQ:GTHX)
www.americanbankingnews.com - August 3 at 12:01 PM
G1 Therapeutics and Simcere Announce Exclusive License Agreement for Trilaciclib in Greater ChinaG1 Therapeutics and Simcere Announce Exclusive License Agreement for Trilaciclib in Greater China
finance.yahoo.com - August 3 at 7:28 AM
G1 Therapeutics Inc (NASDAQ:GTHX) Sees Large Increase in Short InterestG1 Therapeutics Inc (NASDAQ:GTHX) Sees Large Increase in Short Interest
www.americanbankingnews.com - August 1 at 9:46 PM
G1 Therapeutics (GTHX) Set to Announce Quarterly Earnings on WednesdayG1 Therapeutics (GTHX) Set to Announce Quarterly Earnings on Wednesday
www.americanbankingnews.com - July 30 at 10:25 AM
G1 Therapeutics to Provide Second Quarter 2020 Corporate and Financial Update on  August 5, 2020G1 Therapeutics to Provide Second Quarter 2020 Corporate and Financial Update on August 5, 2020
finance.yahoo.com - July 29 at 8:20 AM
G1 Therapeutics (NASDAQ:GTHX) Stock Price Down 7.5%G1 Therapeutics (NASDAQ:GTHX) Stock Price Down 7.5%
www.americanbankingnews.com - July 28 at 9:01 PM
Wedbush Research Analysts Lift Earnings Estimates for G1 Therapeutics Inc (NASDAQ:GTHX)Wedbush Research Analysts Lift Earnings Estimates for G1 Therapeutics Inc (NASDAQ:GTHX)
www.americanbankingnews.com - July 27 at 1:10 AM
G1 Therapeutics Inc (NASDAQ:GTHX) Given Average Recommendation of "Buy" by BrokeragesG1 Therapeutics Inc (NASDAQ:GTHX) Given Average Recommendation of "Buy" by Brokerages
www.americanbankingnews.com - July 26 at 5:10 AM
G1 Therapeutics inks lerociclib deal with EQRxG1 Therapeutics inks lerociclib deal with EQRx
seekingalpha.com - July 23 at 6:04 AM
G1 Therapeutics Announces License Agreement for LerociclibG1 Therapeutics Announces License Agreement for Lerociclib
finance.yahoo.com - July 22 at 6:08 PM
 Analysts Expect G1 Therapeutics Inc (NASDAQ:GTHX) to Post -$0.85 EPS Analysts Expect G1 Therapeutics Inc (NASDAQ:GTHX) to Post -$0.85 EPS
www.americanbankingnews.com - July 16 at 4:25 PM
G1 Therapeutics inks trilaciclib promotion deal with Boehringer IngelheimG1 Therapeutics inks trilaciclib promotion deal with Boehringer Ingelheim
seekingalpha.com - July 1 at 7:15 PM
G1 Therapeutics and Boehringer Ingelheim Announce Co-Promotion Agreement for Trilaciclib in Small Cell Lung Cancer in the United States and Puerto RicoG1 Therapeutics and Boehringer Ingelheim Announce Co-Promotion Agreement for Trilaciclib in Small Cell Lung Cancer in the United States and Puerto Rico
finance.yahoo.com - June 30 at 5:20 PM
Were Hedge Funds Right About Betting On G1 Therapeutics, Inc. (GTHX)?Were Hedge Funds Right About Betting On G1 Therapeutics, Inc. (GTHX)?
finance.yahoo.com - June 30 at 5:20 PM
G1 Therapeutics Has Multiple Roadmaps To A Multi-Billion Dollar Market CapG1 Therapeutics Has Multiple Roadmaps To A Multi-Billion Dollar Market Cap
seekingalpha.com - June 24 at 6:24 PM
RTP firm inks potential $46 million deal for cancer treatment in AsiaRTP firm inks potential $46 million deal for cancer treatment in Asia
www.bizjournals.com - June 22 at 6:41 PM
G1 Therapeutics inks lerociclib deal with Genor BiopharmaG1 Therapeutics inks lerociclib deal with Genor Biopharma
seekingalpha.com - June 22 at 8:39 AM
G1 Therapeutics and Genor Biopharma Announce Exclusive License Agreement for Lerociclib in Asia-Pacific RegionG1 Therapeutics and Genor Biopharma Announce Exclusive License Agreement for Lerociclib in Asia-Pacific Region
finance.yahoo.com - June 22 at 8:39 AM
How G1 Therapeutics (GTHX) Stock Stands Out in a Strong IndustryHow G1 Therapeutics (GTHX) Stock Stands Out in a Strong Industry
finance.yahoo.com - June 11 at 10:00 AM
G1 Therapeutics secures $100M in debt financingG1 Therapeutics secures $100M in debt financing
seekingalpha.com - June 1 at 7:50 PM
G1 Therapeutics Announces Flexible Credit Financing for Up to $100 Million with Hercules CapitalG1 Therapeutics Announces Flexible Credit Financing for Up to $100 Million with Hercules Capital
finance.yahoo.com - June 1 at 7:50 PM
GTHX G1 Therapeutics, Inc. Common StockGTHX G1 Therapeutics, Inc. Common Stock
www.nasdaq.com - May 22 at 11:31 PM
G1 Therapeutics to Present Data Showing Myelopreservation Benefits of Trilaciclib in Patients with Small Cell Lung Cancer at the ASCO20 Virtual Scientific ProgramG1 Therapeutics to Present Data Showing Myelopreservation Benefits of Trilaciclib in Patients with Small Cell Lung Cancer at the ASCO20 Virtual Scientific Program
finance.yahoo.com - May 13 at 6:08 PM
G1 Therapeutics, Inc. (GTHX) CEO Mark Velleca on Q1 2020 Results - Earnings Call TranscriptG1 Therapeutics, Inc. (GTHX) CEO Mark Velleca on Q1 2020 Results - Earnings Call Transcript
seekingalpha.com - May 10 at 4:55 PM
G1 Therapeutics, Inc. (GTHX) Q1 2020 Earnings Call TranscriptG1 Therapeutics, Inc. (GTHX) Q1 2020 Earnings Call Transcript
finance.yahoo.com - May 7 at 3:14 PM
G1 Therapeutics EPS beats by $0.16G1 Therapeutics EPS beats by $0.16
seekingalpha.com - May 7 at 4:28 AM
G1 Therapeutics Provides First Quarter 2020 Corporate and Financial UpdateG1 Therapeutics Provides First Quarter 2020 Corporate and Financial Update
finance.yahoo.com - May 7 at 4:28 AM
We Think G1 Therapeutics (NASDAQ:GTHX) Can Afford To Drive Business GrowthWe Think G1 Therapeutics (NASDAQ:GTHX) Can Afford To Drive Business Growth
finance.yahoo.com - May 6 at 8:02 AM
G1 Therapeutics to Provide First Quarter 2020 Corporate and Financial Update on May 6, 2020G1 Therapeutics to Provide First Quarter 2020 Corporate and Financial Update on May 6, 2020
finance.yahoo.com - April 29 at 10:30 AM
G1 Therapeutics to Present at 19th Annual Needham Virtual Healthcare Conference on April 14, 2020G1 Therapeutics to Present at 19th Annual Needham Virtual Healthcare Conference on April 14, 2020
finance.yahoo.com - April 7 at 6:02 PM
Cover Story: Triangle life sciences gasping for capital, leadersCover Story: Triangle life sciences gasping for capital, leaders
finance.yahoo.com - March 13 at 8:15 AM
G1 Therapeutics Announces Appointment of New Board Member and Chief Commercial OfficerG1 Therapeutics Announces Appointment of New Board Member and Chief Commercial Officer
finance.yahoo.com - March 12 at 9:28 AM
G1 Therapeutics EPS beats by $0.02G1 Therapeutics EPS beats by $0.02
seekingalpha.com - February 26 at 6:24 PM
G1 Therapeutics Provides Fourth Quarter and Full-Year 2019 Corporate and Financial UpdateG1 Therapeutics Provides Fourth Quarter and Full-Year 2019 Corporate and Financial Update
finance.yahoo.com - February 26 at 6:24 PM
G1 Therapeutics to Present at Investor Conferences in March 2020G1 Therapeutics to Present at Investor Conferences in March 2020
finance.yahoo.com - February 24 at 9:18 AM
G1 Therapeutics to Provide Fourth Quarter and Full Year 2019 Corporate and Financial Update on February 26, 2020G1 Therapeutics to Provide Fourth Quarter and Full Year 2019 Corporate and Financial Update on February 26, 2020
finance.yahoo.com - February 19 at 7:34 AM
G1 Therapeutics to Participate in BTIG Targeted...G1 Therapeutics to Participate in BTIG Targeted...
www.benzinga.com - February 17 at 9:26 AM
G1 Therapeutics Presents Updated Data from Phase 1b/2a Trial of Oral CDK4/6 Inhibitor Lerociclib at 2019 San Antonio BreastG1 Therapeutics Presents Updated Data from Phase 1b/2a Trial of Oral CDK4/6 Inhibitor Lerociclib at 2019 San Antonio Breast
www.bloomberg.com - February 11 at 6:35 PM
G1 Therapeutics to Participate in Guggenheim...G1 Therapeutics to Participate in Guggenheim...
www.benzinga.com - February 6 at 8:27 AM
G1 Therapeutics to Participate in Guggenheim Health Talks: Oncology Day on February 13, 2020G1 Therapeutics to Participate in Guggenheim Health Talks: Oncology Day on February 13, 2020
finance.yahoo.com - February 6 at 8:27 AM
Quantum Leap Healthcare Collaborative and G1 Therapeutics Announce the Selection of Trilaciclib in the I-SPY 2 TRIAL for Breast CancerQuantum Leap Healthcare Collaborative and G1 Therapeutics Announce the Selection of Trilaciclib in the I-SPY 2 TRIAL for Breast Cancer
finance.yahoo.com - January 14 at 7:55 AM
G1 Therapeutics to Present at 38th Annual J.P. Morgan Healthcare ConferenceG1 Therapeutics to Present at 38th Annual J.P. Morgan Healthcare Conference
finance.yahoo.com - January 7 at 7:18 AM
BRIEF-G1 Therapeutics Presents Data From Phase 1B/2A Trial Of Lerociclib At 2019 San Antonio Breast Cancer SymposiumBRIEF-G1 Therapeutics Presents Data From Phase 1B/2A Trial Of Lerociclib At 2019 San Antonio Breast Cancer Symposium
www.msn.com - December 12 at 10:12 PM
G1 Therapeutics Presents Updated Data from Phase 1b/2a Trial of Oral CDK4/6 Inhibitor Lerociclib at 2019 San Antonio Breast Cancer Symposium (SABCS)G1 Therapeutics Presents Updated Data from Phase 1b/2a Trial of Oral CDK4/6 Inhibitor Lerociclib at 2019 San Antonio Breast Cancer Symposium (SABCS)
finance.yahoo.com - December 11 at 7:14 PM
This page was last updated on 8/6/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.